Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Schicha

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Zeitschrift Fur Medizinische Physik|July 2, 2011
Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?Wolfgang Eschner, Carsten Kobe, Harald Schicha
International Journal of Radiation Biology|December 9, 2008
Diethylstilbestrol (DES) labeled with Auger emitters: potential radiopharmaceutical for therapy of estrogen receptor-positive tumors and their metastases?Thomas Fischer, Klaus Schomacker, Harald Schicha
European Journal of Nuclear Medicine and Molecular Imaging|August 8, 2009
PROLARA: prognosis-based lifetime attributable risk approximation for cancer from diagnostic radiation exposureWolfgang Eschner, Matthias Schmidt, Markus Dietlein, et al.
Nuklearmedizin. Nuclear Medicine|June 18, 2004
[Subclinical thyroid disease]Harald Schicha, Christoph Reiners, Ernst Moser, et al.
Clinical Nuclear Medicine|October 21, 2006
False-positive uptake of I-131 in a laryngocele mimicking thyroid remnant after thyroidectomy for papillary thyroid carcinomaMatthias Schmidt, Markus Dietlein, Ursula Schröder, et al.
Zeitschrift Fur Medizinische Physik|October 11, 2011
GATE based Monte Carlo simulation of planar scintigraphy to estimate the nodular dose in radioiodine therapy for autonomous thyroid adenomaJochen Hammes, Uwe Pietrzyk, Matthias Schmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2008
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97Matthias Schmidt, Thorsten Simon, Barbara Hero, et al.
Nuclear Medicine Communications|December 18, 2004
Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?Markus Dietlein, Walter A Luyken, Harald Schicha, et al.
The American Journal of Medicine|May 30, 2002
Differentiation between healthy thyroid remnants and tumor tissue after radioiodine therapy in patients with differentiated thyroid carcinoma using in vitro phosphorus-31 magnetic resonance spectroscopyDetlef Moka, Markus Dietlein, Klaus Raffelt, et al.
Journal of Neurology|July 14, 2011
Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's diseaseDeniz Kahraman, Carsten Eggers, Harald Schicha, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Zeitschrift Fur Medizinische Physik|July 2, 2011
Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?Wolfgang Eschner, Carsten Kobe, Harald Schicha
International Journal of Radiation Biology|December 9, 2008
Diethylstilbestrol (DES) labeled with Auger emitters: potential radiopharmaceutical for therapy of estrogen receptor-positive tumors and their metastases?Thomas Fischer, Klaus Schomacker, Harald Schicha
European Journal of Nuclear Medicine and Molecular Imaging|August 8, 2009
PROLARA: prognosis-based lifetime attributable risk approximation for cancer from diagnostic radiation exposureWolfgang Eschner, Matthias Schmidt, Markus Dietlein, et al.
Nuklearmedizin. Nuclear Medicine|June 18, 2004
[Subclinical thyroid disease]Harald Schicha, Christoph Reiners, Ernst Moser, et al.
Clinical Nuclear Medicine|October 21, 2006
False-positive uptake of I-131 in a laryngocele mimicking thyroid remnant after thyroidectomy for papillary thyroid carcinomaMatthias Schmidt, Markus Dietlein, Ursula Schröder, et al.
Zeitschrift Fur Medizinische Physik|October 11, 2011
GATE based Monte Carlo simulation of planar scintigraphy to estimate the nodular dose in radioiodine therapy for autonomous thyroid adenomaJochen Hammes, Uwe Pietrzyk, Matthias Schmidt, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2008
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97Matthias Schmidt, Thorsten Simon, Barbara Hero, et al.
Nuclear Medicine Communications|December 18, 2004
Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?Markus Dietlein, Walter A Luyken, Harald Schicha, et al.
The American Journal of Medicine|May 30, 2002
Differentiation between healthy thyroid remnants and tumor tissue after radioiodine therapy in patients with differentiated thyroid carcinoma using in vitro phosphorus-31 magnetic resonance spectroscopyDetlef Moka, Markus Dietlein, Klaus Raffelt, et al.
Journal of Neurology|July 14, 2011
Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's diseaseDeniz Kahraman, Carsten Eggers, Harald Schicha, et al.
Pageof 5